Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Zillow Group Inc Class A (ZG) Price & Performance

Bristol-Myers Squibb CoTrade
Zillow Group Inc Class ATrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Zillow Group Inc Class A — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while Zillow Group Inc Class A trades at $34.4 (market cap $7.68B). The key difference: Bristol-Myers Squibb Co is far larger — about 16.9× Zillow Group Inc Class A's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.

BMYZG
Market Cap
$129.94B$7.68B
Sector
HealthMedia
52-Week High
$65.89$86.76
52-Week Low
$42.60$29.14
Enterprise Value
$163.92B$7.56B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Zillow Group Inc Class A

Zillow Group (ZG) trades at $33.46, down 1.81% with a bearish technical signal. The company shows improving fundamentals with Q2 2026 earnings beats and 18% revenue growth, though net margins remain thin at 1.96%. Recent news highlights strong performance in the preferred agent model but is overshadowed by multiple securities class action lawsuits with August 2026 deadlines. Valuation metrics appear elevated with a P/E of 149, while analyst consensus targets $47.56 with mixed ratings.

The outlook is cautiously optimistic given ZG's business model transition and revenue growth, but significant legal overhangs and high valuation create near-term risks. Long-term potential exists if monetization improvements continue, though investors should weigh legal uncertainties against fundamental progress.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Zillow Group Inc Class A

Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.

Read more on ZG